What is the Efficiency When Comparing Active Sentry at Low IOP vs Ozil at High IOP?

Sponsor
Cataract and Laser Institute of Southern Oregon (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05868772
Collaborator
Sengi (Industry)
70
1
12
5.8

Study Details

Study Description

Brief Summary

The objective is to assess the efficiency of the Active Sentry handpiece at low intraocular pressure (IOP) compared with the Ozil at high IOP.

Condition or Disease Intervention/Treatment Phase
  • Device: Active Sentry Handpiece
  • Device: Ozil Handpiece

Detailed Description

This study is a single site, single-masked, randomized, prospective, contralateral eye study of the efficiency of the Active Sentry handpiece at low IOP compared with the Ozil at high IOP.

Study Design

Study Type:
Observational
Anticipated Enrollment :
70 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
What is the Efficiency When Comparing Active Sentry at Low IOP vs Ozil at High IOP?
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Sentry Handpiece

At low IOP settings

Device: Active Sentry Handpiece
With low IOP settings

Ozil Handpiece

At high IOP settings

Device: Ozil Handpiece
With high IOP settings.

Outcome Measures

Primary Outcome Measures

  1. Total aspiration time [Day of surgery (Day 0)]

Secondary Outcome Measures

  1. Total fluid volume [Day of surgery (Day 0)]

  2. Total phaco time [Day of surgery (Day 0)]

  3. Aspiration time during phaco [Day of surgery (Day 0)]

  4. Central corneal thickness [1 week postoperative]

Other Outcome Measures

  1. Cumulative dissipated energy [Day of surgery (Day 0)]

    The amount of ultrasound energy used to remove a cataractous lens.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

  • Be eligible to undergo sequential bilateral uncomplicated cataract surgery.

  • Undergo uneventful cataract surgery.

  • Gender: Males and Females.

  • Both eyes must have same grade of cataract.

  • Willing and able to provide written informed consent for participation in the study.

  • Willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Patient under 50 years of age.

  • Unable to complete sequential bilateral cataract surgery in both eyes by the same surgeon (JS).

  • Patient cataract surgery complicated by posterior capsular tear.

  • Any disease state deemed by PI that increases risk of complicated cataract surgery (ie Pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma, RA, prior refractive surgery, etc).

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cataract & Laser Institute Medford Oregon United States 97504

Sponsors and Collaborators

  • Cataract and Laser Institute of Southern Oregon
  • Sengi

Investigators

  • Principal Investigator: Justin Spaulding, DO, Cataract and Laser Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cataract and Laser Institute of Southern Oregon
ClinicalTrials.gov Identifier:
NCT05868772
Other Study ID Numbers:
  • JS-23-01
First Posted:
May 22, 2023
Last Update Posted:
May 22, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 22, 2023